
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">33091053</article-id><article-id pub-id-type="pmc">7580989</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0240880</article-id><article-id pub-id-type="publisher-id">PONE-D-20-25400</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Cytotoxic T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Cytotoxic T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Cytotoxic T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject><subj-group><subject>Cytotoxic T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Medical Risk Factors</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral Transmission and Infection</subject><subj-group><subject>Viral Load</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Suppression</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Suppression</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Immune Suppression</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia</article-title><alt-title alt-title-type="running-head">CD4+ T-cell recovery during long-term ART</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1181-1461</contrib-id><name><surname>Wolday</surname><given-names>Dawit</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Project administration</role><role content-type="https://casrai.org/credit/">Resources</role><role content-type="https://casrai.org/credit/">Supervision</role><role content-type="https://casrai.org/credit/">Validation</role><role content-type="https://casrai.org/credit/">Writing &#x02013; original draft</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Legesse</surname><given-names>Dorsisa</given-names></name><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Project administration</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kebede</surname><given-names>Yazezew</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Writing &#x02013; original draft</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Siraj</surname><given-names>Dawd S.</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Funding acquisition</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Supervision</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>McBride</surname><given-names>Joseph A.</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Striker</surname><given-names>Robert</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Funding acquisition</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Project administration</role><role content-type="https://casrai.org/credit/">Resources</role><role content-type="https://casrai.org/credit/">Supervision</role><role content-type="https://casrai.org/credit/">Validation</role><role content-type="https://casrai.org/credit/">Writing &#x02013; original draft</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Mekelle University College of Health Sciences, Mekelle, Ethiopia</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Hayat General Hospital, Addis Ababa, Ethiopia</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, Wisconsin, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>L&#x000f3;pez-Gal&#x000ed;ndez</surname><given-names>Cecilio</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Instituto de Salud Carlos III, SPAIN</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>dawwol@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>15</volume><issue>10</issue><elocation-id>e0240880</elocation-id><history><date date-type="received"><day>13</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>6</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Wolday et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Wolday et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0240880.pdf"/><abstract><sec id="sec001"><title>Background</title><p>There is very little data on long-term immune recovery responses in patients on suppressive antiretroviral therapy (ART) in the setting of sub-Saharan Africa (SSA). Thus, we sought to determine CD4+ T-cell, CD8+ T-cell and CD4/CD8 ratio responses in a cohort of HIV infected individuals on sustained suppressive ART followed up for more than a decade.</p></sec><sec id="sec002"><title>Methods</title><p>The cohort comprised adult patients who started ART between 2001 and 2007 and followed for up to 14 years. Trends in median CD4+ T-cells, CD8+ T-cells and CD4/CD8 ratio were reviewed retrospectively. Poisson regression models were used to identify factors associated with achieving normalized T-cell biomarkers. Kaplan-Meier curves were used to estimate the probability of attaining normalized counts while on suppressive ART.</p></sec><sec id="sec003"><title>Results</title><p>A total of 227 patients with a median duration of follow-up on ART of 12 (IQR: 10.5&#x02013;13.0) years were included. CD4 cell count increased from baseline median of 138 cells (IQR: 70&#x02013;202) to 555 cells (IQR: 417&#x02013;830). CD4 cell increased continuously up until 5 years, after which it plateaued up until 14 years of follow up. Only 69.6% normalized their CD4 cell count within a median of 6.5 (IQR: 3.0&#x02013;10.5) years. In addition, only 15.9% of the cohort were able to achieve the median reference CD4+ T-cell threshold count in Ethiopians (&#x02248;760 cells/&#x003bc;L). CD8+ T-cell counts increased initially until year 1, after which continuous decrease was ascertained. CD4/CD8 ratio trend revealed continuous increase throughout the course of ART, and increased from a median baseline of 0.14 (IQR: 0.09&#x02013;0.22) to a median of 0.70 (IQR: 0.42&#x02013;0.95). However, only 12.3% normalized their ratio (&#x02265; 1.0) after a median of 11.5 years. In addition, only 8.8% of the cohort were able to achieve the median reference ratio of healthy Ethiopians.</p></sec><sec id="sec004"><title>Conclusion</title><p>Determination of both CD4+ and CD8+ T-cells, along with CD4/CD8 ratio is highly relevant in long-term follow-up of patients to assess immune recovery. Monitoring ratio levels may serve as a better biomarker risk for disease progression among patients on long-term ART. In addition, the findings emphasize the relevance of initiation of ART at the early stage of HIV-1 infection.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100008028</institution-id><institution>School of Medicine and Public Health, University of Wisconsin-Madison</institution></institution-wrap></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1181-1461</contrib-id><name><surname>Wolday</surname><given-names>Dawit</given-names></name></principal-award-recipient></award-group><funding-statement>The project was supported by the Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, USA.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The relevant data are available in the Figshare repository at: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.13072787">https://doi.org/10.6084/m9.figshare.13072787</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The relevant data are available in the Figshare repository at: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.13072787">https://doi.org/10.6084/m9.figshare.13072787</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Effective antiretroviral therapy (ART) suppresses HIV replication allowing progressive immune recovery which is used commonly to assess the status of disease progression [<xref rid="pone.0240880.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0240880.ref002" ref-type="bibr">2</xref>]. ART programs in sub-Saharan Africa (SSA) have achieved outcomes comparable to those in developed countries, especially in terms of immunological and virological responses despite differences in HIV-1 genetic diversity [<xref rid="pone.0240880.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0240880.ref006" ref-type="bibr">6</xref>].</p><p>Reports on outcomes to ART in patients followed up for more than a decade are documented mostly from high-income countries (HICs) [<xref rid="pone.0240880.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0240880.ref012" ref-type="bibr">12</xref>]. On the other hand, reports from SSA on outcomes of ART are those of short duration and long-term treatment outcomes, by large, are hardly known despite the fact that patients are living longer [<xref rid="pone.0240880.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0240880.ref014" ref-type="bibr">14</xref>]. In addition, there are no data with respect to long-term CD4/CD8 ratio responses among patients taking ART in SSA. Despite effective viral suppression, however, immune recovery is often incomplete, which very often remains below the normal threshold levels [<xref rid="pone.0240880.ref015" ref-type="bibr">15</xref>&#x02013;<xref rid="pone.0240880.ref024" ref-type="bibr">24</xref>]. Incomplete immune recovery despite ART has been linked with increased mortality and morbidity, both due to AIDS-related and non-AIDS-related or non-communicable diseases [<xref rid="pone.0240880.ref024" ref-type="bibr">24</xref>&#x02013;<xref rid="pone.0240880.ref034" ref-type="bibr">34</xref>], and monitoring the ratio appears to be both relatively simple and comprehensive way of evaluating changing risks for clinical events.</p><p>We have previously shown that apparently healthy HIV-negative adult Ethiopians exhibit low CD4+ T-cell count and CD4/CD8 ratio compared to Caucasians [<xref rid="pone.0240880.ref035" ref-type="bibr">35</xref>&#x02013;<xref rid="pone.0240880.ref039" ref-type="bibr">39</xref>]. Despite low baseline CD4+ T-cell count or CD4/CD8 ratio among Ethiopians, HIV disease progression during pre-ART era remained the same in the two populations [<xref rid="pone.0240880.ref038" ref-type="bibr">38</xref>]. In settings, like ours, very low CD4+ T-cell count and low CD4/CD8 ratio in apparently healthy HIV-seronegative individuals poses challenge for ART guidelines based on normal reference threshold values. Hence, we sought to determine immune recovery among Ethiopian patients initiated with ART followed up for more than a decade. In addition, we determined factors associated with immune recovery in this patient population.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><sec id="sec007"><title>Study population</title><p>The cohort was enrolled at Hayat General Hospital&#x02019;s ART Clinic in Addis Ababa, Ethiopia, which delivers HIV treatment and care [<xref rid="pone.0240880.ref040" ref-type="bibr">40</xref>]. The cohort consists of adult patients followed between 2001 and 2017. Patients with an AIDS defining illness or a CD4 count &#x0003c;200 cell/&#x003bc;L were started on with a combination of ART, based on National ART Guidelines [<xref rid="pone.0240880.ref041" ref-type="bibr">41</xref>]. First-line ART comprised of zidovudine (AZT) or stavudine (d4T) or tenofovir (TDF) in combination with lamivudine (3TC) plus non-nucleoside reverse transcriptase inhibitors, nevirapine (NVP) or efavirenz (EFV). The participants had clinic visits every 6 months and/or as needed for monitoring treatment outcomes. Laboratory tests performed during each visit included complete blood cell count, clinical chemistry, urine analysis, and immune-profiles (as measured by CD4 cell count, CD8 cell count and CD4/CD8 ratio). CD4, CD8 and CD4/CD8 ratio was measured using FACSCount (BD Biosciences, San Jose, USA). HIV-1 plasma viral load determination was done by real-time nucleic-acid sequence-based amplification (NASBA) using the NUCLISENSE EASYQ technology (BioM&#x000e9;rieux, Boxtel, The Netherlands). The lower limit of detection (LDL) of the assay is 50 RNA copies/mL blood. HIV-1 viral load was done for patients in the event of clinical or immunological failure, as per National Guidelines [<xref rid="pone.0240880.ref041" ref-type="bibr">41</xref>]. Clinical failure is suspected when new or recurring WHO clinical stage III or IV event occurs, and immunological failure is considered when the CD4 count is persistently &#x0003c; 250 cells/&#x003bc;L, or there is persistent CD4 count levels &#x0003c; 100 cells/&#x003bc;L.</p><p>Patients were censored at the time of CD4, CD8 or CD4/CD8 ratio normalization, at the time of death, transfer to other clinic, loss to follow-up, or the last visit date before December 2017. CD4 count, CD8 count and CD4/CD8 ratio are considered normalized if &#x02265; 500 cells, between 500 and 1000 cells, and &#x02265; 1.0, respectively (based on values of healthy adult Ethiopians [<xref rid="pone.0240880.ref035" ref-type="bibr">35</xref>&#x02013;<xref rid="pone.0240880.ref039" ref-type="bibr">39</xref>]). Viral suppression was defined as the attainment of HIV-1 plasma viral load of &#x0003c;400 copies/mL on at least two subsequent measurements. Poor adherence was defined as intake of prescribed medications &#x0003c;95%, based on National ART Guidelines [<xref rid="pone.0240880.ref041" ref-type="bibr">41</xref>]. Adherence was monitored based on pill counts during clinic visits, self-report as well as by checking pharmacy refill records.</p></sec><sec id="sec008"><title>Statistical analysis</title><p>Baseline characteristics for continuous variables were expressed as the median with interquartile range (IQR), and for categorical variables as proportions. Chi-square test was used to compare categorical variables and Wilcoxon rank-sum test for not normally distributed variables.</p><p>The rate of T-cell marker normalization was calculated per 100 person years at risk. Factors associated with probability of T-cell marker normalization were analyzed using Poisson regression analysis. Using univariate analysis, we initially analyzed the relative risk (RR) of not achieving CD4+ T-cell count normalization with respect to baseline demographic and clinical characteristics (age, gender and HIV disease stage, TDF-based regimen), presence of tuberculosis (TB) at time of ART initiation and baseline laboratory biomarkers including CD4+ T-cell count, CD8+ T-cell count, CD4/CD8 ratio and plasma viral load. In addition, time-dependent variables including drug toxicity, ART adherence, ART switching, as well as updated T-cell markers were included in the initial bivariate analysis. Then a multivariate analysis of probability [adjusted relative risk (ARR)] of achieving CD4 count &#x02265; 500 cells was done including all variables that were significant in univariate analysis.</p><p>Baseline CD4+ T-cell counts were built in to two categories whether normalized (&#x02265;500) or not normalized (&#x0003c;500) cells/&#x003bc;L, the CD8 cell counts in three categories (&#x0003c;500, between 500 and 1000, and &#x0003e;1000 cells/&#x003bc;L), and the CD4/CD8 ratio in two categories (&#x0003c;0.30 and &#x02265;0.30). The cut-offs were chosen based on previous reports showing association of the biomarkers with AIDS-related events [<xref rid="pone.0240880.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0240880.ref032" ref-type="bibr">32</xref>, <xref rid="pone.0240880.ref040" ref-type="bibr">40</xref>].</p><p>Kaplan-Meier curves were used to estimate the probability of CD4+ T-cell count normalization in patients on ART across explanatory variables and statistical differences were tested using log-rank test. P values &#x0003c;0.05 were considered statistically significant. Data was entered on excel and exported for analysis by STATA (Statistical package v. 14.0, StataCorp, Texas, USA).</p></sec><sec id="sec009"><title>Ethical considerations</title><p>The study was reviewed and approved by the Addis Ababa City Administration Health Bureau Research Ethics Review Committee, Addis Ababa, Ethiopia and the Institutional Review Board (IRB) of the University of Wisconsin, Madison, USA. As the nature of the study was retrospective, individual study participant consent was not obtained and approved by the ethics review committee. Nonetheless, all personal identifiers were de-linked from the original sources.</p></sec></sec><sec sec-type="results" id="sec010"><title>Results</title><sec id="sec011"><title>Characteristics of study participants</title><p>Socio-demographic and baseline clinical features are shown in <xref rid="pone.0240880.t001" ref-type="table">Table 1</xref>. A total of 227 patients receiving ART and with sustained virological suppression were included in the study. The median age at ART initiation was 39 years (IQR: 33&#x02013;46) years. The majority were male (63.4%) with more than half (56.8%) being in Stage III and IV WHO clinical stage.</p><table-wrap id="pone.0240880.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0240880.t001</object-id><label>Table 1</label><caption><title>Sociodemographic and clinical characteristics.</title></caption><alternatives><graphic id="pone.0240880.t001g" xlink:href="pone.0240880.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Overall</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Total patients</bold></td><td align="center" rowspan="1" colspan="1">227 (100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median years, (IQR)</td><td align="center" rowspan="1" colspan="1">39 (33&#x02013;46)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Sex</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">144 (63.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" rowspan="1" colspan="1">83 (36.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>WHO Clinical Stage</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;I/II</td><td align="center" rowspan="1" colspan="1">98 (43.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;III/IV</td><td align="center" rowspan="1" colspan="1">129 (56.8)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Adverse drug effects</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="center" rowspan="1" colspan="1">203 (89.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">24 (10.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ART adherence</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Good</td><td align="center" rowspan="1" colspan="1">210 (92.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Poor</td><td align="center" rowspan="1" colspan="1">17 (7.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ART switching</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="center" rowspan="1" colspan="1">86 (37.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">141 (62.1)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD4 cell count (cells/&#x003bc;L) at baseline</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median (IQR)</td><td align="center" rowspan="1" colspan="1">138 (70&#x02013;202)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c; 200</td><td align="center" rowspan="1" colspan="1">167 (74.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265; 200</td><td align="center" rowspan="1" colspan="1">57 (25.4)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD8 cell count (cells/&#x003bc;L) at baseline</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median (IQR)</td><td align="center" rowspan="1" colspan="1">899 (645&#x02013;1266)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c; 500</td><td align="center" rowspan="1" colspan="1">25 (12.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;500&#x02013;1000</td><td align="center" rowspan="1" colspan="1">93 (45.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;1000</td><td align="center" rowspan="1" colspan="1">88 (42.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD4/CD8 ratio at baseline</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median (IQR)</td><td align="center" rowspan="1" colspan="1">0.14 (0.09&#x02013;0.22)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c; 0.30</td><td align="center" rowspan="1" colspan="1">178 (86.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265; 0.30</td><td align="center" rowspan="1" colspan="1">28 (13.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Viral load (RNA copies/mL) at baseline</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median (IQR)</td><td align="center" rowspan="1" colspan="1">120 000 (27 000&#x02013;280 000)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Follow-up [median (IQR) Years]</bold></td><td align="center" rowspan="1" colspan="1">12.0 (10.5&#x02013;13.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ART regimen</bold></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;AZT+3TC+ EFV</td><td align="center" rowspan="1" colspan="1">91 (40.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;d4T+3TC+ EFV</td><td align="center" rowspan="1" colspan="1">60 (26.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;d4T+3TC+ NVP</td><td align="center" rowspan="1" colspan="1">31 (13.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TDF+3TC+EFV</td><td align="center" rowspan="1" colspan="1">18 (7.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;AZT+3TC+ NVP</td><td align="center" rowspan="1" colspan="1">16 (7.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TDF+3TC+NVP</td><td align="center" rowspan="1" colspan="1">4 (1.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PI containing</td><td align="center" rowspan="1" colspan="1">6 (2.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other</td><td align="center" rowspan="1" colspan="1">2 (0.9)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Data are numbers (%) unless otherwise stated. ART = antiretroviral therapy; IQR = interquartile range.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec012"><title>Trends of T-cell biomarkers</title><p>Trends of the CD4+ T-cell, CD8+ T-cell and CD4/CD8 ratio is shown in <xref ref-type="fig" rid="pone.0240880.g001">Fig 1</xref>. The CD4 cell count increased from baseline median of 138 (IQR: 70&#x02013;202) to 555 (IQR: 417&#x02013;830) cells/&#x003bc;L after a median of 12 (IQR: 10.5&#x02013;13.0) years of follow up on ART (p&#x0003c;0.0001) (<xref ref-type="fig" rid="pone.0240880.g001">Fig 1A</xref>). The increase of CD4 T cells exhibited a biphasic pattern. It increased continuously from baseline median of 138 (IQR: 70&#x02013;202) to 510 (IQR: 385&#x02013;653) cells/ &#x003bc;L after a median of 7.5 years of follow up on ART (p&#x0003c;0.00001). However, beyond 7.5 years of ART, the CD4+ T-cell count plateaued and there is no significant change when the median CD4 cell count at year 5 was compared to the median CD4 cell count at year 14 of follow up on ART (p = 0.8588). Whereas the median increase of CD4 count per year (slope) was 38 (IQR: 30&#x02013;57) cells/&#x003bc;L in phase one, it plateaued at around -1 (-13&#x02013;25) cells/&#x003bc;L per year in phase two of the follow-up (p = 0.0109). Continuous increases in the median CD4+ T-cell counts in both groups with baseline CD4/CD8 ratio of less than 0.30 and &#x02265; 0.30 were observed, though increases were more significant in the group with baseline CD4/CD8 ratio of &#x02265; 0.30 (<xref ref-type="fig" rid="pone.0240880.g001">Fig 1B</xref>). The median increase of CD4 count per year in those with baseline CD4/CD8 ratio &#x02265; 0.30 was 43 (IQR: 28&#x02013;53) cells/&#x003bc;L up until 8.5 years compared to only 7 (IQR: -18&#x02013;33) cells/&#x003bc;L after 8.5 years of follow-up. In addition, the median increase of CD4 count per year in those with baseline ratio &#x0003c; 0.30 was 33 (IQR: 16&#x02013;55) cells/&#x003bc;L up until 5 years, but only 4 (IQR: -18&#x02013;10) cells/&#x003bc;L after 5 years of follow-up. Overall, only 69.6% of the cohort has normalized CD4 cell count (&#x02265;500 cells) during the 2631.6 person-years of follow-up, and the median time to CD4 count normalization was 6.5 (IQR: 3.0&#x02013;10.5) years. In addition, only 15.9% of the cohort were able to achieve the median reference CD4+ T-cell threshold count in Ethiopians, which is &#x02248;760 cells [<xref rid="pone.0240880.ref035" ref-type="bibr">35</xref>]. The median time to reach the reference CD4 cell count threshold of Ethiopians was 12 (IQR: 10.8&#x02013;13.3) years.</p><fig id="pone.0240880.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0240880.g001</object-id><label>Fig 1</label><caption><title>Trends in CD4+ T-cell (A), CD8+ T-cell (C) counts and CD4/CD8 ratio (E) among all patients with virologically suppressive ART, or trends in CD4+ T-cell (B), CD8+ T-cell (D) counts and CD4/CD8 ratio (F) in those stratified by baseline ratio &#x0003c; 0.30 or &#x02265; 0.30.</title><p>Data represent median (IQR) for A, C and E, or as median only for B, D and F. Dashed horizontal lines across figures A, C and E represent normal reference threshold values in healthy Ethiopians [<xref rid="pone.0240880.ref034" ref-type="bibr">34</xref>].</p></caption><graphic xlink:href="pone.0240880.g001"/></fig><p>Trends in CD8 T cell count exhibited a three phase pattern, with initial increase up until 1 year, followed by plateau until 6 years and decline after 6 years of ART follow-up (<xref ref-type="fig" rid="pone.0240880.g001">Fig 1C</xref>). CD8+ T-cell counts increased initially until year 1, after which continuous decrease in CD8+ T-cell count was ascertained. Overall, there was no significant change in CD8+ T-cells when baseline counts were compared to those at 14 years. However, there was statistically significant decrease in CD8+ T-cells when median count at year 1 [1063 (IQR: 754&#x02013;1490) cells/&#x003bc;L was compared to the median count at year 14 [911 (IQR: 788&#x02013;1154) cells/&#x003bc;L] on ART (p = 0.005). Although decrease in CD8+ T-cell count between year 1 and 6 was not significant, significant decrease was noted between year 6 and year 14 of follow up [986 (IQR: 730&#x02013;1322 cells/&#x003bc;L) vs. 911 (IQR: 788&#x02013;1154 cells/&#x003bc;L), p = 0.009]. In the early phase until year 1, the median increase of CD8 count per year was 81(IQR: 0&#x02013;162) cells/&#x003bc;L. The median change of CD8 count per year between the years 1 and 6 was -28 (IQR: -35&#x02013;1) cells/&#x003bc;L, and between the years 7 and 14 was 3 (IQR: -41&#x02013;10) cells/&#x003bc;L. However, the changes were not statistically significant. Although, the median CD8 count decline per year was -23 (-41&#x02013;10) cells/&#x003bc;L after 1 year of follow-up, it was not statistically significant compared to the slope noted up until 1 year (p = 0.2341). CD8 T cell trends stratified by CD4/CD8 ratio did not show any pattern (<xref ref-type="fig" rid="pone.0240880.g001">Fig 1D</xref>).</p><p>The CD4/CD8 ratio trends revealed continuous increase throughout the course of ART, and increased from a median baseline of 0.14 (IQR: 0.09&#x02013;0.22) to a median of 0.70 (IQR: 0.42&#x02013;0.95) at the time of censoring the study (p = 0.0003) (<xref ref-type="fig" rid="pone.0240880.g001">Fig 1E</xref>). However, only 12.3% of the cohort has normalized ratio (&#x02265; 1.0). The median time to ratio normalization was 11.5 (95% CI: 10.0&#x02013;12.5) years. Continuous increases in the median CD4/CD8 ratio were more significant in the group with a baseline ratio of &#x02265; 0.30 than in those with less than 0.30. In the latter group, slight increase in ratio were noted up until year 4 on ART, then it plateaued (<xref ref-type="fig" rid="pone.0240880.g001">Fig 1F</xref>). The overall CD4/CD8 ratio increase per year (slope) was 0.04 (IQR: 0.02&#x02013;0.05). The median increase of CD4/CD8 ratio per year in those with baseline ratio &#x02265; 0.30 was 0.03 (IQR: 0.02&#x02013;0.06). On the other hand, the trend in ratio change for those with a baseline &#x0003c; 0.30 showed somewhat biphasic pattern. Whereas the median increase in CD4/CD8 ratio up until 9 years of follow-up was 0.02 (IQR: 0.01&#x02013;0.04), it decreased by a median ratio of -0.01 (IQR: -0.02&#x02013;0.03) beyond 9 years. However, the difference was not statistically significant (p = 0.0847). In addition, only 8.8% of the cohort were able to achieve the median reference ratio threshold value of healthy Ethiopians, which is &#x02248;1.10 [<xref rid="pone.0240880.ref035" ref-type="bibr">35</xref>]. Overall, the proportion of patients with a CD4/CD8 ratio of &#x02265; 0.3, &#x02265; 0.5, &#x02265;0.8, &#x02265; 1.0 and &#x02265; 1.2 were 85.5%, 57.3%, 26.9%, 12.3% and 6.6%, respectively (<xref ref-type="supplementary-material" rid="pone.0240880.s001">S1 Fig</xref>).</p></sec><sec id="sec013"><title>Factors associated with immune recovery</title><p>Predictors associated with failure to achieve CD4+ T-cell normalization &#x02265; 500 is shown in <xref rid="pone.0240880.t002" ref-type="table">Table 2</xref>. On univariate analysis female sex (RR: 2.26, 95% CI: 1.26&#x02013;4.07), CD4+ T-cell count &#x0003c; 200 cells at baseline (RR: 2.93, 95%CI 1.34&#x02013;6.24), and CD4/CD8 ratio at baseline (per 0.1 point lower) (RR: 1.57, 95%CI 1.19&#x02013;2.07) were all associated with failure to achieve CD4+ T-cell normalization. On the contrary, age, WHO clinical stage, adverse drug events, adherence, ART switching, TDF-based regimen, prevalent or incident TB, AIDS-defining events, non-AIDS-defining events, CD8+ T-cell count and baseline plasma viral load were all not associated with failure to achieve CD4 normalization.</p><table-wrap id="pone.0240880.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0240880.t002</object-id><label>Table 2</label><caption><title>Factors associated with not achieving CD4+ T-cell count &#x02265; 500 in HIV-infected patients on antiretroviral treatment despite sustained viral suppression.</title></caption><alternatives><graphic id="pone.0240880.t002g" xlink:href="pone.0240880.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Univariate</th><th align="center" colspan="3" rowspan="1">Multivariate</th></tr><tr><th align="left" rowspan="1" colspan="1">RR (95% CI)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" rowspan="1" colspan="1">ARR (95% CI)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Age (years)</bold> &#x02265; 50 vs. &#x0003c; 50</td><td align="center" rowspan="1" colspan="1">1.75 (0.90&#x02013;3.43)</td><td align="char" char="." rowspan="1" colspan="1">0.100</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gender, male vs female</bold></td><td align="center" rowspan="1" colspan="1">2.26 (1.26&#x02013;4.07)</td><td align="char" char="." rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">1.64 (0.88&#x02013;3.06)</td><td align="char" char="." rowspan="1" colspan="1">0.120</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>WHO stage</bold> III/IV vs. I/II</td><td align="center" rowspan="1" colspan="1">1.11 (0.69&#x02013;1.80)</td><td align="char" char="." rowspan="1" colspan="1">0.664</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Adverse drug events vs none</bold></td><td align="center" rowspan="1" colspan="1">1.11 (0.53&#x02013;2.32)</td><td align="char" char="." rowspan="1" colspan="1">0.783</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Poor vs good adherence</bold></td><td align="center" rowspan="1" colspan="1">0.97 (0.39&#x02013;2.40)</td><td align="char" char="." rowspan="1" colspan="1">0.939</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ART switch vs. no switch</bold></td><td align="center" rowspan="1" colspan="1">0.95 (0.59&#x02013;1.54)</td><td align="char" char="." rowspan="1" colspan="1">0.831</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TB at ART initiation vs. no TB</bold></td><td align="center" rowspan="1" colspan="1">1.86 (0.85&#x02013;4.06)</td><td align="char" char="." rowspan="1" colspan="1">0.120</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Incident TB vs. no TB</bold></td><td align="center" rowspan="1" colspan="1">1.53 (0.80&#x02013;2.92)</td><td align="char" char="." rowspan="1" colspan="1">0.194</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>AIDS-defining events vs. none</bold></td><td align="center" rowspan="1" colspan="1">1.29 (0.74&#x02013;2.22)</td><td align="char" char="." rowspan="1" colspan="1">0.367</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Non-AIDS-defining events vs none</bold></td><td align="center" rowspan="1" colspan="1">1.29 (0.74&#x02013;2.26)</td><td align="char" char="." rowspan="1" colspan="1">0.369</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD4+ T-cell count at baseline</bold>&#x0003c; 200 vs. &#x02265; 200</td><td align="center" rowspan="1" colspan="1">2.93 (1.34&#x02013;6.40)</td><td align="char" char="." rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">1.82 (0.78&#x02013;4.21)</td><td align="char" char="." rowspan="1" colspan="1">0.165</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD8+ T-cell count at baseline</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;500&#x02013;1000</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">--</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;500</td><td align="center" rowspan="1" colspan="1">0.55 (0.21&#x02013;1.40)</td><td align="char" char="." rowspan="1" colspan="1">0.208</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;1000</td><td align="center" rowspan="1" colspan="1">0.78 (0.46&#x02013;1.30)</td><td align="char" char="." rowspan="1" colspan="1">0.338</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CD4/CD8 ratio at baseline</bold> (per 0.1 lower)</td><td align="center" rowspan="1" colspan="1">1.57(1.19&#x02013;2.06)</td><td align="char" char="." rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">1.36 (1.01&#x02013;1.82)</td><td align="char" char="." rowspan="1" colspan="1">0.041</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Viral load at baseline (RNA copies/mL)</bold> &#x02265; 100,000 vs. &#x0003c; 100,000<xref ref-type="table-fn" rid="t002fn002">*</xref></td><td align="center" rowspan="1" colspan="1">0.98 (0.41&#x02013;2.33)</td><td align="char" char="." rowspan="1" colspan="1">0.964</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>RR: relative risk; ARR: adjusted relative risk;</p></fn><fn id="t002fn002"><p>*Data available for only 59 patients at baseline.</p></fn></table-wrap-foot></table-wrap><p>In multivariate analysis, however, baseline CD4/CD8 ratio (per 0.1 point lower) (ARR: 1.36, 95% CI: 1.01&#x02013;1.82, p = 041) was the only factor associated with increased probability of failure to achieve CD4+ T-cell normalization.</p></sec></sec><sec sec-type="conclusions" id="sec014"><title>Discussion</title><p>Data on long-term outcomes of ART in the setting of SSA are limited [<xref rid="pone.0240880.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0240880.ref014" ref-type="bibr">14</xref>]. Here, we measured CD4+ T-cell count, CD8+ T-cell count and CD4/CD8 ratio during a median of 12 years with sustained virological suppression in HIV-1 infected patients on ART.</p><p>The CD4+ T-cell trends showed continuous increase up until year 5&#x02013;7 of follow up, but plateaued thereafter. Median reference CD4+ T-cell count [<xref rid="pone.0240880.ref035" ref-type="bibr">35</xref>] was achieved within an average of 12 years follow-up in only 15% of the patients. In addition, using multivariate analysis, the likelihood of achieving CD4+ T-cell count normalization (&#x02265; 500 cells) was significantly associated with time-updated CD4/CD8 ratio &#x02265; 0.30 at ART initiation. In addition, similar to previous studies undertaken in HICs [<xref rid="pone.0240880.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0240880.ref012" ref-type="bibr">12</xref>] and SSA [<xref rid="pone.0240880.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0240880.ref014" ref-type="bibr">14</xref>], our findings showed that the majority of the patients (76%) started ART with a CD4+ T-cell lower than 200 cells. Only 4 patients were initiated ART with their CD4+ T-cell counts &#x02265; 350 cells. Therefore, we did not analyze the effect on CD4+ T-cell normalization when patients were initiated with ART when their CD4+ T-cell count was &#x02265; 350 cells. Nonetheless, several studies conducted previously have demonstrated that baseline CD4+ T-cell count &#x02265; 350 is a significant predictor of achieving CD4+ T-cell normalization [<xref rid="pone.0240880.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0240880.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0240880.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0240880.ref024" ref-type="bibr">24</xref>]. In our study, baseline CD4/CD8 ratio was the only factor associated with the likelihood of achieving normalized CD4+ T-cell count. Previous studies have demonstrated similar results [<xref rid="pone.0240880.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0240880.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0240880.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0240880.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0240880.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0240880.ref042" ref-type="bibr">42</xref>&#x02013;<xref rid="pone.0240880.ref048" ref-type="bibr">48</xref>].</p><p>CD8+ T-cell counts increased during the first year, but remained persistently elevated up until year 6. However, after 6 years, it decreased continuously in subsequent years of follow up on ART. CD8+ T-cell count appears to play important role in mortality in patients on ART [<xref rid="pone.0240880.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0240880.ref049" ref-type="bibr">49</xref>] and need to be monitored for clinical assessment.</p><p>CD4/CD8 ratio was the only biomarker that showed continuous increase throughout the follow up period. Like the CD4+ T-cell trend, however, only 12.3% of the cohort has normalized ratio (&#x02265; 1.0) and few patients (8.8%) were able to attain a median reference ratio value of HIV-negative Ethiopians [<xref rid="pone.0240880.ref035" ref-type="bibr">35</xref>]. Whereas the initial increase in the CD4/CD8 ratio between ART initiation and year 5 of follow-up might be attributed to the continuous increase in the CD4+ T-cell count as CD8+ T-cells remained persistently elevated. However, in the later phase of ratio increase (i.e. year 6 to 14) might be attributed to the continuous decrease in CD8+ T-cells as the CD4+ T-cell count in the same period plateaued. Previous report from HICs showed trends whereby the increase of CD4 counts and decrease of CD8 counts appeared to be similar [<xref rid="pone.0240880.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0240880.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0240880.ref030" ref-type="bibr">30</xref>]. Nonetheless, the trends to normalization time in the Ethiopian cohort appears to be much slower than those in HICs, similar to the cohort in Uganda [<xref rid="pone.0240880.ref014" ref-type="bibr">14</xref>]. In addition, the time to reach plateau was even shorter in the HICs when compared to our results.</p><p>Our data demonstrate that the measurement of both CD4+ and CD8+ T-cells, along with the assessment of the CD4/CD8 ratio are highly relevant in long-term follow-up and evaluation of patients with respect to immune recovery. Taken together, all T-cell biomarkers (i.e. CD4+ T-cell count, CD8+ T-cell count and CD4/CD8 ratio) failed to normalize to the levels of healthy individuals despite long-term virologically suppressive ART.</p><p>The mechanisms related to incomplete immune recovery in patients on ART despite suppressive ART remains to be elucidated. Several studies have demonstrated that chronic immune activation [<xref rid="pone.0240880.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0240880.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0240880.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0240880.ref030" ref-type="bibr">30</xref>], older age [<xref rid="pone.0240880.ref024" ref-type="bibr">24</xref>], male sex [<xref rid="pone.0240880.ref050" ref-type="bibr">50</xref>, <xref rid="pone.0240880.ref051" ref-type="bibr">51</xref>], background genetic differences [<xref rid="pone.0240880.ref022" ref-type="bibr">22</xref>] might play significant role.</p><p>Our study has several strengths. First, the cohort included a long-term of follow-up of HIV-1 patients on sustained suppressive ART for more than a decade. Second, data on immune recovery biomarkers was availability both at initiation of ART and also time-dependent changes in CD4+ T-cell, CD8+ T-cell counts and CD4/CD8 ratio were obtained. Third, to the best of our knowledge, our study included long-term analysis of CD4/CD8 ratio in patients under suppressive ART in the setting of SSA. Nonetheless, limitations related to our study include that our findings cannot be generalized to the entire population as the data is generated from only one study site. Furthermore, the retrospective design of the study has limitations in respect to completeness of available data and the small sample size is a potential weakness of the study. In particular relevant data that are potentially confounders, such as parasitic infections and malnutrition were not available or incomplete. Finally, the number of patients during follow-up of such long duration is compounded by patient attrition. Thus, interpretation of our data after 10 years where a substantial number of patient followed is decreased showing unstable trends.</p><sec id="sec015"><title>Conclusion</title><p>Our data demonstrate that the measurement of both CD4+ and CD8+ T-cells, along with the assessment of the CD4/CD8 ratio is highly relevant in long-term follow-up and evaluation of patients with respect to immune recovery. In addition, our findings show that the majority (76%) of the patients started ART with a CD4+ T-cell lower than 200 cells, and all the T-cell biomarkers (CD4+ T-cell count, CD8+ T-cell count and CD4/CD8 ratio) did not normalize to the levels of healthy individuals despite long-term virologically suppressive ART. The results emphasize the relevance of initiation of ART at the early stage of HIV-1 infection [<xref rid="pone.0240880.ref051" ref-type="bibr">51</xref>&#x02013;<xref rid="pone.0240880.ref053" ref-type="bibr">53</xref>].</p><p>Whether current &#x0201c;treat-all&#x0201d; ART guidelines [<xref rid="pone.0240880.ref054" ref-type="bibr">54</xref>] will result in complete immunological recovery in the setting of SSA should be investigated. In addition, continuous increase in CD4/CD8 ratio while CD4+ T-cell count plateau after 5 years of ART initiation in our study suggests that monitoring ratio levels may serve as a better biomarker risk for disease progression monitoring among patients on long-term ART.</p></sec></sec><sec sec-type="supplementary-material" id="sec016"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0240880.s001"><label>S1 Fig</label><caption><title>Proportion of patients with different CD4/CD8 ratio cut-offs.</title><p>(TIF)</p></caption><media xlink:href="pone.0240880.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank all patients for participating in the study. We would like to thank the management and staff of Hayat General Hospital, College of Health Sciences, Addis Ababa, Ethiopia for their technical support and allowing us to conduct this study.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>ART</term><def><p>antiretroviral treatment</p></def></def-item><def-item><term>HICs</term><def><p>high-income countries</p></def></def-item><def-item><term>HIV</term><def><p>human immunodeficiency virus</p></def></def-item><def-item><term>IQR</term><def><p>interquartile range</p></def></def-item><def-item><term>LICs</term><def><p>low-income countries</p></def></def-item><def-item><term>SSA</term><def><p>Sub-Saharan Africa</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0240880.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Battegay</surname><given-names>M</given-names></name>, <name><surname>N&#x000fc;esch</surname><given-names>R</given-names></name>, <name><surname>Hirschel</surname><given-names>B</given-names></name>, <name><surname>Kaufmann</surname><given-names>GR</given-names></name>. <article-title>Immunological recovery and antiretroviral therapy in HIV-1 infection</article-title>. <source>Lancet Infect Dis</source>
<year>2006</year>; <volume>6</volume>:<fpage>280</fpage>&#x02013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(06)70463-7</pub-id>
<pub-id pub-id-type="pmid">16631548</pub-id></mixed-citation></ref><ref id="pone.0240880.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Mocroft</surname><given-names>A</given-names></name>, <name><surname>Phillips</surname><given-names>A</given-names></name>, <name><surname>Gatell</surname><given-names>J</given-names></name>, <name><surname>Ledergerber</surname><given-names>B</given-names></name>, <name><surname>Fisher</surname><given-names>M</given-names></name>, <name><surname>Clumeck</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Normalisation of CD4 counts in patients with HIV infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study</article-title>. <source>Lancet</source>
<year>2007</year>; <volume>370</volume>:<fpage>407</fpage>&#x02013;<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60948-9</pub-id>
<pub-id pub-id-type="pmid">17659333</pub-id></mixed-citation></ref><ref id="pone.0240880.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Ivers</surname><given-names>LC</given-names></name>, <name><surname>Kendrick</surname><given-names>D</given-names></name>, <name><surname>Doucette</surname><given-names>K</given-names></name>. <article-title>efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature</article-title>. <source>Clin Infect Dis</source>
<year>2005</year>; <volume>41</volume>: <fpage>217</fpage>&#x02013;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1086/431199</pub-id>
<pub-id pub-id-type="pmid">15983918</pub-id></mixed-citation></ref><ref id="pone.0240880.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Geng</surname><given-names>EH</given-names></name>, <name><surname>Neilands</surname><given-names>TB</given-names></name>, <name><surname>Thiebaut</surname><given-names>R</given-names></name>, <name><surname>Bwana</surname><given-names>MB</given-names></name>, <name><surname>Nash</surname><given-names>D</given-names></name>, <name><surname>Moore</surname><given-names>RD</given-names></name>, <etal>et al</etal>
<article-title>CD4+ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa</article-title>. <source>Int J Epidemiol</source>. <year>2015</year>; <volume>44</volume>:<fpage>251</fpage>&#x02013;<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1093/ije/dyu271</pub-id>
<pub-id pub-id-type="pmid">25859596</pub-id></mixed-citation></ref><ref id="pone.0240880.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Barth</surname><given-names>RE</given-names></name>, <name><surname>van der Loeff</surname><given-names>MF</given-names></name>, <name><surname>Schuurman</surname><given-names>R</given-names></name>, <name><surname>Hoepelman</surname><given-names>AI</given-names></name>, <name><surname>Wensing</surname><given-names>AM</given-names></name>. <article-title>Virological follow-up of adult patients on antiretroviral treatment programs in Sub-Saharan Africa: a systematic review</article-title>. <source>Lancet Infect Dis</source>
<year>2010</year>; <volume>10</volume>: <fpage>155</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(09)70328-7</pub-id>
<pub-id pub-id-type="pmid">20185094</pub-id></mixed-citation></ref><ref id="pone.0240880.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Nash</surname><given-names>D</given-names></name>, <name><surname>Katyal</surname><given-names>M</given-names></name>, <name><surname>Brinkhof</surname><given-names>MWG</given-names></name>, <name><surname>Keiser</surname><given-names>O</given-names></name>, <name><surname>May</surname><given-names>M</given-names></name>, <name><surname>Hughes</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Long-term response to antiretroviral therapy in low-income countries</article-title>. <source>AIDS</source>
<year>2008</year>; <volume>22</volume>: <fpage>2292</fpage>&#x02013;<lpage>2302</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e3283121ca9</pub-id>
<pub-id pub-id-type="pmid">18981768</pub-id></mixed-citation></ref><ref id="pone.0240880.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Nakanjako</surname><given-names>D</given-names></name>, <name><surname>Kiragga</surname><given-names>AN</given-names></name>, <name><surname>Musick</surname><given-names>BS</given-names></name>, <name><surname>Yiannoutsos</surname><given-names>CT</given-names></name>, <name><surname>Wools-Kaloustian</surname><given-names>K</given-names></name>, <name><surname>Diero</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the international epidemiologic databases to evaluate AIDS in East Africa</article-title>. <source>AIDS</source>. <year>2016</year>; <volume>30</volume>:<fpage>1913</fpage>&#x02013;<lpage>1922</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0000000000001085</pub-id>
<pub-id pub-id-type="pmid">26959510</pub-id></mixed-citation></ref><ref id="pone.0240880.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>R&#x000f6;nsholt</surname><given-names>FF</given-names></name>, <name><surname>Ullum</surname><given-names>H</given-names></name>, <name><surname>Katzenstein</surname><given-names>TL</given-names></name>, <name><surname>Gerstoft</surname><given-names>J</given-names></name>, <name><surname>Ostrowski</surname><given-names>SR</given-names></name>. <article-title>T-cell subset distribution in HIV-1-infected patients after 12 years of treatment-induced viremic suppression</article-title>. <source>J Acquir Immune Defic Syndr</source>
<year>2012</year>; <volume>61</volume>:<fpage>270</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e31825e7ac1</pub-id>
<pub-id pub-id-type="pmid">22614900</pub-id></mixed-citation></ref><ref id="pone.0240880.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Torti</surname><given-names>C</given-names></name>, <name><surname>Prosperi</surname><given-names>M</given-names></name>, <name><surname>Motta</surname><given-names>D</given-names></name>, <name><surname>Digiambenedetto</surname><given-names>S</given-names></name>, <name><surname>Maggiolo</surname><given-names>F</given-names></name>, <name><surname>Paraninfo</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy</article-title>. <source>Clin Microbiol Infect</source>
<year>2012</year>; <volume>18</volume>:<fpage>449</fpage>&#x02013;<lpage>458</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03650.x</pub-id>
<pub-id pub-id-type="pmid">21919996</pub-id></mixed-citation></ref><ref id="pone.0240880.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Hunt</surname><given-names>PW</given-names></name>, <name><surname>Hammer</surname><given-names>SM</given-names></name>, <etal>et al</etal>
<article-title>Immune activation while on potent antiretroviral therapy can predict subsequent CD4+ T-cell increases through 15 years of treatment</article-title>. <source>HIV Clin Trials</source>. <year>2013</year>; <volume>14</volume>:<fpage>61</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1310/hct1402-61</pub-id>
<pub-id pub-id-type="pmid">23611826</pub-id></mixed-citation></ref><ref id="pone.0240880.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Hughes</surname><given-names>RA</given-names></name>, <name><surname>May</surname><given-names>MT</given-names></name>, <name><surname>Tilling</surname><given-names>K</given-names></name>, <name><surname>Taylor</surname><given-names>N</given-names></name>, <name><surname>Wittkop</surname><given-names>L</given-names></name>, <name><surname>Reiss</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Long-term trends in CD4+ cell counts, CD8+ cell counts, and the CD4+:CD8+ ratio</article-title>. <source>Clin Infect Dis</source>
<year>2018</year>; <volume>32</volume>: <fpage>1361</fpage>&#x02013;<lpage>1367</lpage>
<pub-id pub-id-type="doi">10.1097/QAD.0000000000001848</pub-id>
<pub-id pub-id-type="pmid">29851663</pub-id></mixed-citation></ref><ref id="pone.0240880.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Mutoh</surname><given-names>Y</given-names></name>, <name><surname>Nishijima</surname><given-names>T</given-names></name>, <name><surname>Inaba</surname><given-names>Y</given-names></name>, <name><surname>Tanaka</surname><given-names>N</given-names></name>, <name><surname>Kikuchi</surname><given-names>Y</given-names></name>, <name><surname>Gatanaga</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Incomplete recovery of CD4 cell count, CD4 percentage, and CD4/CD8 ratio in patients with human immunodeficiency virus infection and suppressed viremia during long-term antiretroviral therapy</article-title>. <source>Clin Infect Dis</source>
<year>2018</year>; <volume>67</volume>:<fpage>927</fpage>&#x02013;<lpage>933</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciy176</pub-id>
<pub-id pub-id-type="pmid">29509894</pub-id></mixed-citation></ref><ref id="pone.0240880.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Ndumbi</surname><given-names>P</given-names></name>, <name><surname>Falutz</surname><given-names>J</given-names></name>, <name><surname>Pant Pai</surname><given-names>N</given-names></name>, <name><surname>Tsoukas</surname><given-names>CM</given-names></name>. <article-title>Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression</article-title>. <source>PLoS One</source>
<year>2014</year>; <volume>9</volume>:<fpage>e94018</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0094018</pub-id>
<pub-id pub-id-type="pmid">24710051</pub-id></mixed-citation></ref><ref id="pone.0240880.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Castelnuovo</surname><given-names>B</given-names></name>, <name><surname>Kiragga</surname><given-names>A</given-names></name>, <name><surname>Musaazi</surname><given-names>J</given-names></name>, <name><surname>Sempa</surname><given-names>J</given-names></name>, <name><surname>Mubiru</surname><given-names>F</given-names></name>, <name><surname>Wanyama</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Outcomes in a cohort of patients started on antiretroviral treatment and followed up for a decade in an urban clinic in Uganda</article-title>. <source>PLoS ONE</source>
<year>2015</year>; <volume>10</volume>: <fpage>e0142722</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0142722</pub-id>
<pub-id pub-id-type="pmid">26642214</pub-id></mixed-citation></ref><ref id="pone.0240880.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Kaufmann</surname><given-names>GR</given-names></name>, <name><surname>Furrer</surname><given-names>H</given-names></name>, <name><surname>Ledergerber</surname><given-names>B</given-names></name>, <name><surname>Perrin</surname><given-names>L</given-names></name>, <name><surname>Opravil</surname><given-names>M</given-names></name>, <name><surname>Vernazza</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Characteristics, determinants, and clinical relevance of CD4 T cell recovery to &#x0003c;500 cells/uL in HIV type 1-infected individuals receiving potent antiretroviral therapy</article-title>. <source>Clin Infect Dis</source>
<year>2005</year>; <volume>41</volume>:<fpage>361</fpage>&#x02013;<lpage>372</lpage>. <pub-id pub-id-type="doi">10.1086/431484</pub-id>
<pub-id pub-id-type="pmid">16007534</pub-id></mixed-citation></ref><ref id="pone.0240880.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Khanna</surname><given-names>N</given-names></name>, <name><surname>Opravil</surname><given-names>M</given-names></name>, <name><surname>Furrer</surname><given-names>H</given-names></name>, <name><surname>Cavassini</surname><given-names>M</given-names></name>, <name><surname>Vernazza</surname><given-names>P</given-names></name>, <name><surname>Bernasconi</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy</article-title>. <source>Clin Infect Dis</source>
<year>2008</year>; <volume>47</volume>:<fpage>1093</fpage>&#x02013;<lpage>1101</lpage>. <pub-id pub-id-type="doi">10.1086/592113</pub-id>
<pub-id pub-id-type="pmid">18783328</pub-id></mixed-citation></ref><ref id="pone.0240880.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Gaardbo</surname><given-names>JC</given-names></name>, <name><surname>Hartling</surname><given-names>HJ</given-names></name>, <name><surname>Gerstoft</surname><given-names>J</given-names></name>, <name><surname>Nielsen</surname><given-names>SD</given-names></name>. <article-title>Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions</article-title>. <source>Clin Dev Immunol</source>
<year>2012</year>; <volume>2012</volume>:<fpage>670957</fpage>
<pub-id pub-id-type="doi">10.1155/2012/670957</pub-id>
<pub-id pub-id-type="pmid">22474480</pub-id></mixed-citation></ref><ref id="pone.0240880.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Emu</surname><given-names>B</given-names></name>, <name><surname>Moretto</surname><given-names>WJ</given-names></name>, <name><surname>Hoh</surname><given-names>R</given-names></name>, <name><surname>Krone</surname><given-names>M</given-names></name>, <name><surname>Martin</surname><given-names>JN</given-names></name>, <name><surname>Nixon</surname><given-names>DF</given-names></name>, <etal>et al</etal>
<article-title>Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease</article-title>. <source>PLoS One</source>
<year>2014</year>; <volume>9</volume>:<fpage>e85613</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0085613</pub-id>
<pub-id pub-id-type="pmid">24465619</pub-id></mixed-citation></ref><ref id="pone.0240880.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Hunt</surname><given-names>PW</given-names></name>, <name><surname>Martin</surname><given-names>JN</given-names></name>, <name><surname>Sinclair</surname><given-names>E</given-names></name>, <name><surname>Bredt</surname><given-names>B</given-names></name>, <name><surname>Hagos</surname><given-names>E</given-names></name>, <name><surname>Lampiris</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus infected patients with sustained viral suppression during antiretroviral therapy</article-title>. <source>J Infect Dis</source>. <year>2003</year>; <volume>187</volume>:<fpage>1534</fpage>&#x02013;<lpage>1543</lpage>. <pub-id pub-id-type="doi">10.1086/374786</pub-id>
<pub-id pub-id-type="pmid">12721933</pub-id></mixed-citation></ref><ref id="pone.0240880.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Massanella</surname><given-names>M</given-names></name>, <name><surname>Negredo</surname><given-names>E</given-names></name>, <name><surname>Perez-Alvarez</surname><given-names>N</given-names></name>, <name><surname>Puig</surname><given-names>J</given-names></name>, <name><surname>Hernandez</surname><given-names>RR</given-names></name>, <name><surname>Bofill</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART</article-title>. <source>AIDS</source>. <year>2010</year>; <volume>24</volume>:<fpage>959</fpage>&#x02013;<lpage>968</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e328337b957</pub-id>
<pub-id pub-id-type="pmid">20177358</pub-id></mixed-citation></ref><ref id="pone.0240880.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Kroeze</surname><given-names>S</given-names></name>, <name><surname>Wit</surname><given-names>FW</given-names></name>, <name><surname>Rossouw</surname><given-names>TM</given-names></name>, <name><surname>Steel</surname><given-names>HC</given-names></name>, <name><surname>Kityo</surname><given-names>CM</given-names></name>, <name><surname>Siwale</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Plasma biomarkers of human immunodeficiency virus-related systemic inflammation and immune activation in Sub-Saharan Africa before and during suppressive antiretroviral therapy</article-title>. <source>J Infect Dis</source>. <year>2019</year>; <volume>220</volume>:<fpage>1029</fpage>&#x02013;<lpage>1033</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiz252</pub-id>
<pub-id pub-id-type="pmid">31086991</pub-id></mixed-citation></ref><ref id="pone.0240880.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Seng</surname><given-names>R</given-names></name>, <name><surname>Ghislain</surname><given-names>M</given-names></name>, <name><surname>Girard</surname><given-names>PM</given-names></name>, <name><surname>Cotte</surname><given-names>L</given-names></name>, <name><surname>Meybeck</surname><given-names>A</given-names></name>, <name><surname>Raffi</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Sub-Saharan African migrants have slower initial CD4+ cell recovery after combined antiretroviral treatment initiation than French natives</article-title>. <source>AIDS</source>. <year>2017</year>; <volume>31</volume>: <fpage>1323</fpage>&#x02013;<lpage>1332</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0000000000001482</pub-id>
<pub-id pub-id-type="pmid">28492394</pub-id></mixed-citation></ref><ref id="pone.0240880.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>RD</given-names></name>, <name><surname>Keruly</surname><given-names>JC</given-names></name>. <article-title>CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virological failure</article-title>. <source>Clin Infect Dis</source>
<year>2007</year>; <volume>44</volume>:<fpage>441</fpage>&#x02013;<lpage>446</lpage>. <pub-id pub-id-type="pmid">17205456</pub-id></mixed-citation></ref><ref id="pone.0240880.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Kroeze</surname><given-names>S</given-names></name>, <name><surname>Ondoa</surname><given-names>P</given-names></name>, <name><surname>Kityo</surname><given-names>CM</given-names></name>, <name><surname>Siwale</surname><given-names>M</given-names></name>, <name><surname>Akanmu</surname><given-names>S</given-names></name>, <name><surname>Wellington</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa</article-title>. <source>AIDS</source>. <year>2018</year>; <volume>32</volume>:<fpage>1043</fpage>&#x02013;<lpage>1051</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0000000000001801</pub-id>
<pub-id pub-id-type="pmid">29547445</pub-id></mixed-citation></ref><ref id="pone.0240880.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Lawn</surname><given-names>SD</given-names></name>, <name><surname>Myer</surname><given-names>L</given-names></name>, <name><surname>Orrell</surname><given-names>C</given-names></name>, <name><surname>Bekker</surname><given-names>LG</given-names></name>, <name><surname>Wood</surname><given-names>R</given-names></name>. <article-title>Early mortality among adults accessing a community based antiretroviral service in South Africa: implications for programme design</article-title>. <source>AIDS</source>
<year>2005</year>; <volume>19</volume>: <fpage>2141</fpage>&#x02013;<lpage>2148</lpage>. <pub-id pub-id-type="doi">10.1097/01.aids.0000194802.89540.e1</pub-id>
<pub-id pub-id-type="pmid">16284464</pub-id></mixed-citation></ref><ref id="pone.0240880.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Lawn</surname><given-names>SD</given-names></name>, <name><surname>Little</surname><given-names>F</given-names></name>, <name><surname>Bekker</surname><given-names>LG</given-names></name>, <name><surname>Kaplan</surname><given-names>R</given-names></name>, <name><surname>Campbel</surname><given-names>E</given-names></name>, <name><surname>Orrell</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa</article-title>. <source>AIDS</source>
<year>2009</year>; <volume>23</volume>: <fpage>335</fpage>&#x02013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e328321823f</pub-id>
<pub-id pub-id-type="pmid">19114870</pub-id></mixed-citation></ref><ref id="pone.0240880.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Young</surname><given-names>J</given-names></name>, <name><surname>Psichogiou</surname><given-names>M</given-names></name>, <name><surname>Meyer</surname><given-names>L</given-names></name>, <name><surname>Ayayi</surname><given-names>S</given-names></name>, <name><surname>Grabar</surname><given-names>S</given-names></name>, <name><surname>Raffi</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE</article-title>. <source>PLoS Med</source>. <year>2012</year>; <volume>9</volume>: <fpage>e1001194</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1001194</pub-id>
<pub-id pub-id-type="pmid">22448150</pub-id></mixed-citation></ref><ref id="pone.0240880.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Loutfy</surname><given-names>MR</given-names></name>, <name><surname>Genebat</surname><given-names>M</given-names></name>, <name><surname>Moore</surname><given-names>D</given-names></name>, <name><surname>Raboud</surname><given-names>J</given-names></name>, <name><surname>Chan</surname><given-names>K</given-names></name>, <name><surname>Antoniou</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>A CD4+ cell count &#x0003c;200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression</article-title>. <source>J Acquir Immune Defic Syndr</source>
<year>2010</year>; <volume>55</volume>: <fpage>451</fpage>&#x02013;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1097/qai.0b013e3181ec28ff</pub-id>
<pub-id pub-id-type="pmid">21105259</pub-id></mixed-citation></ref><ref id="pone.0240880.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Takuva</surname><given-names>S</given-names></name>, <name><surname>Maskew</surname><given-names>M</given-names></name>, <name><surname>Brennan</surname><given-names>AT</given-names></name>, <name><surname>Long</surname><given-names>L</given-names></name>, <name><surname>Sanne</surname><given-names>I</given-names></name>, <name><surname>Fox</surname><given-names>MP</given-names></name>. <article-title>Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort</article-title>. <source>J Int AIDS Soc</source>. <year>2014</year>; <volume>17</volume>:<fpage>18651</fpage>
<pub-id pub-id-type="doi">10.7448/IAS.17.1.18651</pub-id>
<pub-id pub-id-type="pmid">24594114</pub-id></mixed-citation></ref><ref id="pone.0240880.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Serrano-Villar</surname><given-names>S</given-names></name>, <name><surname>Sainz</surname><given-names>T</given-names></name>, <name><surname>Lee</surname><given-names>SA</given-names></name>, <name><surname>Hunt</surname><given-names>PW</given-names></name>, <name><surname>Sinclair</surname><given-names>E</given-names></name>, <name><surname>Shacklett</surname><given-names>BL</given-names></name>, <etal>et al</etal>
<article-title>HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality</article-title>. <source>PLoS Pathog</source>
<year>2014</year>; <volume>10</volume>:<fpage>e1004078</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1004078</pub-id>
<pub-id pub-id-type="pmid">24831517</pub-id></mixed-citation></ref><ref id="pone.0240880.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Mussini</surname><given-names>C</given-names></name>, <name><surname>Lorenzini</surname><given-names>P</given-names></name>, <name><surname>Cozzi-Lepris</surname><given-names>A</given-names></name>, <name><surname>Lapadula</surname><given-names>G</given-names></name>, <name><surname>Marchetti</surname><given-names>G</given-names></name>, <name><surname>Nicastri</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study</article-title>. <source>Lancet HIV</source>
<year>2015</year>; <volume>2</volume>:<fpage>e98</fpage>&#x02013;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/S2352-3018(15)00006-5</pub-id>
<pub-id pub-id-type="pmid">26424550</pub-id></mixed-citation></ref><ref id="pone.0240880.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Serrano-Villar</surname><given-names>S</given-names></name>, <name><surname>Perez-Elias</surname><given-names>MJ</given-names></name>, <name><surname>Dronda</surname><given-names>F</given-names></name>, <name><surname>Casado</surname><given-names>JL</given-names></name>, <name><surname>Moreno</surname><given-names>A</given-names></name>, <name><surname>Royuela</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Increased risk of serious non- AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio</article-title>. <source>PLoS One</source>
<year>2014</year>; <volume>9</volume>:<fpage>e85798</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0085798</pub-id>
<pub-id pub-id-type="pmid">24497929</pub-id></mixed-citation></ref><ref id="pone.0240880.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Trickey</surname><given-names>A</given-names></name>, <name><surname>May</surname><given-names>MT</given-names></name>, <name><surname>Schommers</surname><given-names>P</given-names></name>, <name><surname>Tate</surname><given-names>J</given-names></name>, <name><surname>Ingle</surname><given-names>SM</given-names></name>, <name><surname>Guest</surname><given-names>JL</given-names></name>, <etal>et al</etal>
<article-title>CD4:CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virusinfected patients on antiretroviral therapy: the antiretroviral therapy cohort collaboration (ART-CC)</article-title>. <source>Clin Infect Dis</source>. <year>2017</year>; <volume>65</volume>:<fpage>959</fpage>&#x02013;<lpage>966</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cix466</pub-id>
<pub-id pub-id-type="pmid">28903507</pub-id></mixed-citation></ref><ref id="pone.0240880.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Geltzeiler</surname><given-names>CB</given-names></name>, <name><surname>Xu</surname><given-names>Y</given-names></name>, <name><surname>Carchman</surname><given-names>E</given-names></name>, <name><surname>Ghouse</surname><given-names>Y</given-names></name>, <name><surname>Beczkiewicz</surname><given-names>J</given-names></name>, <name><surname>Son</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>CD4/CD8 ratio as a novel marker of increased risk of high grade anal dysplasia and cancer in HIV+ patients: a retrospective cohort study</article-title>. <source>Dis Col Rec</source>, <year>2020</year>, In press.</mixed-citation></ref><ref id="pone.0240880.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Tsegaye</surname><given-names>A</given-names></name>, <name><surname>Messele</surname><given-names>T</given-names></name>, <name><surname>Tilahun</surname><given-names>T</given-names></name>, <name><surname>Hailu</surname><given-names>E</given-names></name>, <name><surname>Sahlu</surname><given-names>T</given-names></name>, <name><surname>Doorly</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Immunohematological reference ranges for adult Ethiopians</article-title>. <source>Clin Diag Lab Immunol</source>
<year>1999</year>; <volume>6</volume>:<fpage>410</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="pone.0240880.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Kassu</surname><given-names>A</given-names></name>, <name><surname>Tsegaye</surname><given-names>P</given-names></name>, <name><surname>Petros</surname><given-names>B</given-names></name>, <name><surname>Wolday</surname><given-names>D</given-names></name>, <name><surname>Hailu</surname><given-names>E</given-names></name>, <name><surname>Tilahun</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Distribution of lymphocyte subsets in healthy human immunodeficiency virus-negative adult Ethiopians from two geographic locales</article-title>. <source>Clin Diag Lab Immunol</source>
<year>2001</year>; <volume>8</volume>: <fpage>1171</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1128/CDLI.8.6.1171-1176.2001</pub-id></mixed-citation></ref><ref id="pone.0240880.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Kassu</surname><given-names>A</given-names></name>, <name><surname>Tsegaye</surname><given-names>A</given-names></name>, <name><surname>Wolday</surname><given-names>D</given-names></name>, <name><surname>Petros</surname><given-names>B</given-names></name>, <name><surname>Aklilu</surname><given-names>M</given-names></name>, <name><surname>Sanders</surname><given-names>EJ</given-names></name>, <etal>et al</etal>
<article-title>Role of incident and/or cured intestinal parasitic infections on profile of CD4+ and CD8+ T cell subsets and activation status in HIV-infected and uninfected adult Ethiopians</article-title>. <source>Clin Exp Immunol</source>
<year>2003</year>; <volume>132</volume>:<fpage>113</fpage>&#x02013;<lpage>119</lpage>. <pub-id pub-id-type="pmid">12653845</pub-id></mixed-citation></ref><ref id="pone.0240880.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Abuye</surname><given-names>C</given-names></name>, <name><surname>Tsegaye</surname><given-names>A</given-names></name>, <name><surname>West</surname><given-names>CE</given-names></name>, <name><surname>Versloot</surname><given-names>P</given-names></name>, <name><surname>Sanders</surname><given-names>EJ</given-names></name>, <name><surname>Wolday</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Determinants of CD4 counts among HIV-negative Ethiopians: Role of body mass index, gender, cigarette smoking, khat (Catha Edulis) chewing, and possibly altitude?</article-title>
<source>J Clin Immunol</source>
<year>2005</year>; <volume>25</volume>: <fpage>127</fpage>&#x02013;<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1007/s10875-005-2818-y</pub-id>
<pub-id pub-id-type="pmid">15821889</pub-id></mixed-citation></ref><ref id="pone.0240880.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Mekonnen</surname><given-names>Y</given-names></name>, <name><surname>Geskus</surname><given-names>RB</given-names></name>, <name><surname>Hendriks</surname><given-names>JCM</given-names></name>, <name><surname>Messele</surname><given-names>T</given-names></name>, <name><surname>Borghans</surname><given-names>J</given-names></name>, <name><surname>Miedema</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Low CD4 T cell counts before HIV-1 seroconversion do not affect disease progression in Ethiopian factory workers</article-title>. <source>J Infect Dis</source>
<year>2005</year>; <volume>192</volume>: <fpage>739</fpage>&#x02013;<lpage>748</lpage>. <pub-id pub-id-type="doi">10.1086/432545</pub-id>
<pub-id pub-id-type="pmid">16088823</pub-id></mixed-citation></ref><ref id="pone.0240880.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Wolday</surname><given-names>D</given-names></name>, <name><surname>Kebede</surname><given-names>Y</given-names></name>, <name><surname>Legesse</surname><given-names>Y</given-names></name>, <name><surname>Siraj</surname><given-names>DS</given-names></name>, <name><surname>McBride</surname><given-names>JA</given-names></name>, <name><surname>Kirsch</surname><given-names>MJ</given-names></name>, <etal>et al</etal>
<article-title>Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade</article-title>. <source>PLoS One</source>
<year>2020</year>; <volume>15</volume>:<fpage>e0233049</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0233049</pub-id>
<pub-id pub-id-type="pmid">32442166</pub-id></mixed-citation></ref><ref id="pone.0240880.ref041"><label>41</label><mixed-citation publication-type="other">Ministry of Health (MoH). HIV/AIDS Prevention and Control Office. National Guidelines for Use of Antiretroviral Drugs in Ethiopia. MoH, 2001.</mixed-citation></ref><ref id="pone.0240880.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Sauter</surname><given-names>R</given-names></name>, <name><surname>Huang</surname><given-names>R</given-names></name>, <name><surname>Ledergerber</surname><given-names>B</given-names></name>, <name><surname>Battegay</surname><given-names>M</given-names></name>, <name><surname>Bernasconi</surname><given-names>E</given-names></name>, <name><surname>Cavassini</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART</article-title>. <source>Medicine (Baltimore)</source>
<year>2016</year>; <volume>95</volume>: <fpage>e5094</fpage>
<pub-id pub-id-type="doi">10.1097/MD.0000000000005094</pub-id>
<pub-id pub-id-type="pmid">27759638</pub-id></mixed-citation></ref><ref id="pone.0240880.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>W</given-names></name>, <name><surname>Mehraj</surname><given-names>V</given-names></name>, <name><surname>Vyboh</surname><given-names>K</given-names></name>, <name><surname>Cao</surname><given-names>W</given-names></name>, <name><surname>Routy</surname><given-names>JP</given-names></name>. <article-title>CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients</article-title>. <source>J Int AIDS Soc</source>. <year>2015</year>; <volume>18</volume>:<fpage>20052</fpage>
<pub-id pub-id-type="pmid">26130226</pub-id></mixed-citation></ref><ref id="pone.0240880.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Serrano-Villar</surname><given-names>S</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>C</given-names></name>, <name><surname>Vallejo</surname><given-names>A</given-names></name>, <name><surname>Hern&#x000e1;ndez-Novoa</surname><given-names>B</given-names></name>, <name><surname>Diaz</surname><given-names>L</given-names></name>, <name><surname>Abad Fern&#x000e1;ndez</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression</article-title>. <source>J Infect</source>
<year>2013</year>;<volume>66</volume>:<fpage>57</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2012.09.013</pub-id>
<pub-id pub-id-type="pmid">23046968</pub-id></mixed-citation></ref><ref id="pone.0240880.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Tinago</surname><given-names>W</given-names></name>, <name><surname>Coghlan</surname><given-names>E</given-names></name>, <name><surname>Macken</surname><given-names>A</given-names></name>, <name><surname>McAndrews</surname><given-names>J</given-names></name>, <name><surname>Doak</surname><given-names>B</given-names></name>, <name><surname>Prior-Fuller</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Clinical, immunological and treatment-related factors associated with normalized CD4+/CD8+ T-cell ratio: effect of naive and memory T-cell subsets</article-title>. <source><italic toggle="yes">PLoS One</italic></source>
<year>2014</year>; <volume>9</volume>: <fpage>e97011</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0097011</pub-id>
<pub-id pub-id-type="pmid">24816636</pub-id></mixed-citation></ref><ref id="pone.0240880.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Leung</surname><given-names>V</given-names></name>, <name><surname>Gillis</surname><given-names>J</given-names></name>, <name><surname>Raboud</surname><given-names>J</given-names></name>, <name><surname>Cooper</surname><given-names>C</given-names></name>, <name><surname>Hogg</surname><given-names>RS</given-names></name>, <name><surname>Loutfy</surname><given-names>MR</given-names></name>, <etal>et al</etal>
<article-title>Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy</article-title>. <source>PLoS One</source>
<year>2013</year>; <volume>8</volume>:<fpage>e77665</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0077665</pub-id>
<pub-id pub-id-type="pmid">24204912</pub-id></mixed-citation></ref><ref id="pone.0240880.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Caby</surname><given-names>F</given-names></name>, <name><surname>Guihot</surname><given-names>A</given-names></name>, <name><surname>Lambert-Niclot</surname><given-names>S</given-names></name>, <name><surname>Guiguet</surname><given-names>M</given-names></name>, <name><surname>Boutolleau</surname><given-names>D</given-names></name>, <name><surname>Agher</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Determinants of a low CD4/CD8 ratio in HIV-1&#x02013;infected individuals despite long-term viral suppression</article-title>. <source>Clin Infect Dis</source>
<year>2016</year>; <volume>62</volume>:<fpage>1297</fpage>&#x02013;<lpage>1303</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciw076</pub-id>
<pub-id pub-id-type="pmid">26908792</pub-id></mixed-citation></ref><ref id="pone.0240880.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Sainz</surname><given-names>T</given-names></name>, <name><surname>Serrano-Villar</surname><given-names>S</given-names></name>, <name><surname>Diaz</surname><given-names>L</given-names></name>, <name><surname>Tome</surname><given-names>MIG</given-names></name>, <name><surname>Gurbindo</surname><given-names>MD</given-names></name>, <name><surname>Jose</surname><given-names>MI</given-names></name>, <etal>et al</etal>
<article-title>The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults</article-title>. <source>AIDS</source>
<year>2013</year>; <volume>27</volume>:<fpage>1513</fpage>&#x02013;<lpage>1516</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e32835faa72</pub-id>
<pub-id pub-id-type="pmid">23435292</pub-id></mixed-citation></ref><ref id="pone.0240880.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Helleberg</surname><given-names>M</given-names></name>, <name><surname>Kronborg</surname><given-names>G</given-names></name>, <name><surname>Ullum</surname><given-names>H</given-names></name>, <name><surname>Ryder</surname><given-names>LP</given-names></name>, <name><surname>Obel</surname><given-names>N</given-names></name>, <name><surname>Gerstoft</surname><given-names>J</given-names></name>. <article-title>Course and clinical significance of CD8 counts in a large HIV cohort</article-title>. <source>J Infect Dis</source>
<year>2015</year>; <volume>211</volume>:<fpage>1726</fpage>&#x02013;<lpage>1734</lpage>. <pub-id pub-id-type="pmid">25489001</pub-id></mixed-citation></ref><ref id="pone.0240880.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Sempa</surname><given-names>JB</given-names></name>, <name><surname>Kiragga</surname><given-names>AN</given-names></name>, <name><surname>Castelnuovo</surname><given-names>B</given-names></name>, <name><surname>Kamya</surname><given-names>MR</given-names></name>, <name><surname>Manabe</surname><given-names>YC</given-names></name>. <article-title>Among patients with sustained viral suppression in a resource-limited setting, CD4 gains are continuous although gender-based differences occur</article-title>. <source>PLoS ONE</source>
<year>2013</year>; <volume>8</volume>: <fpage>e73190</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0073190</pub-id>
<pub-id pub-id-type="pmid">24013838</pub-id></mixed-citation></ref><ref id="pone.0240880.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Plana</surname><given-names>M</given-names></name>, <name><surname>Garcia</surname><given-names>F</given-names></name>, <name><surname>Gallart</surname><given-names>T</given-names></name>, <name><surname>Tortajada</surname><given-names>C</given-names></name>, <name><surname>Soriano</surname><given-names>A</given-names></name>, <name><surname>Palou</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection</article-title>. <source>AIDS</source>
<year>2000</year>; <volume>14</volume>:<fpage>1921</fpage>&#x02013;<lpage>1933</lpage>. <pub-id pub-id-type="doi">10.1097/00002030-200009080-00007</pub-id>
<pub-id pub-id-type="pmid">10997396</pub-id></mixed-citation></ref><ref id="pone.0240880.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Le</surname><given-names>T</given-names></name>, <name><surname>Wright</surname><given-names>EJ</given-names></name>, <name><surname>Smith</surname><given-names>DM</given-names></name>, <name><surname>Catano</surname><given-names>G</given-names></name>, <name><surname>Okulicz</surname><given-names>JF</given-names></name>, <name><surname>Young</surname><given-names>JA</given-names></name>, <etal>et al</etal>
<article-title>Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy</article-title>. <source>N Engl J Med</source>
<year>2013</year>; <volume>368</volume>:<fpage>218</fpage>&#x02013;<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1110187</pub-id>
<pub-id pub-id-type="pmid">23323898</pub-id></mixed-citation></ref><ref id="pone.0240880.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Thornhill</surname><given-names>J</given-names></name>, <name><surname>Inshaw</surname><given-names>J</given-names></name>, <name><surname>Kaleebu</surname><given-names>P</given-names></name>, <name><surname>Cooper</surname><given-names>D</given-names></name>, <name><surname>Ramjee</surname><given-names>G</given-names></name>, <name><surname>Schechter</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Enhanced normalization of CD4/CD8 ratio with earlier antiretroviral therapy at primary HIV infection</article-title>. <source>J Acquir Immune Defic Syndr</source>
<year>2016</year>; <volume>73</volume>:<fpage>69</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0000000000001013</pub-id>
<pub-id pub-id-type="pmid">27070122</pub-id></mixed-citation></ref><ref id="pone.0240880.ref054"><label>54</label><mixed-citation publication-type="other">World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2017, WHO, Geneva. <ext-link ext-link-type="uri" xlink:href="http://www.apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1">http://www.apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1</ext-link></mixed-citation></ref></ref-list></back></article>